Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Breast Cancer
EGFR
ERBB Receptor Family
HER2
HER3
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
17
05
2022
revised:
07
07
2022
accepted:
10
07
2022
pubmed:
24
7
2022
medline:
24
8
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
Targeting the HER2 oncogene represents one of the greatest advances in the treatment of breast cancer. HER2 is one member of the ERBB-receptor family, which includes EGFR (HER1), HER3 and HER4. In the presence or absence of underling genomic aberrations such as mutations or amplification events, intricate interactions between these proteins on the cell membrane lead to downstream signaling that encourages cancer growth and proliferation. In this Review, we contextualize efforts to pharmacologically target the ErbB receptor family beyond HER2, with a focus on EGFR and HER3. Preclinical and clinical efforts are synthesized. We discuss successes and failures of this approach to date, summarize lessons learned, and propose a way forward that invokes new therapeutic modalities such as antibody drug conjugates (ADCs), combination strategies, and patient selection through rational biomarkers.
Identifiants
pubmed: 35870237
pii: S0305-7372(22)00105-0
doi: 10.1016/j.ctrv.2022.102436
pmc: PMC10478787
mid: NIHMS1928027
pii:
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Receptor, ErbB-3
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102436Subventions
Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Références
Oncology. 2001;61 Suppl 2:1-13
pubmed: 11694782
Ann Oncol. 2018 Jan 1;29(suppl_1):i20-i27
pubmed: 29462255
Lancet Oncol. 2021 Mar;22(3):351-360
pubmed: 33581774
Oncogene. 2011 Jun 2;30(22):2547-57
pubmed: 21278786
Ann Oncol. 2013 Feb;24(2):273-282
pubmed: 22910839
Clin Cancer Res. 2016 Feb 15;22(4):877-85
pubmed: 26463709
J Clin Oncol. 2005 Aug 10;23(23):5323-33
pubmed: 15939921
Drugs. 2018 Jun;78(9):893-911
pubmed: 29915896
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756933
Front Mol Biosci. 2022 Feb 28;9:847835
pubmed: 35295841
J Oncol. 2009;2009:567486
pubmed: 19424511
Curr Opin Cell Biol. 2009 Apr;21(2):177-84
pubmed: 19208461
Int J Cancer. 2016 May 1;138(9):2274-80
pubmed: 26649807
Oncogene. 2020 Jan;39(3):487-502
pubmed: 31519989
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Sci Signal. 2014 Mar 25;7(318):ra29
pubmed: 24667376
J Clin Oncol. 2012 Jul 20;30(21):2615-23
pubmed: 22665533
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1746-50
pubmed: 8383326
Crit Rev Oncol Hematol. 2019 Nov;143:153-163
pubmed: 31678702
Ann Oncol. 2014 Aug;25(8):1570-7
pubmed: 24827135
Cancer Metastasis Rev. 2017 Sep;36(3):463-473
pubmed: 28866730
Crit Rev Oncol Hematol. 2010 May;74(2):73-8
pubmed: 19481955
Breast Cancer Res Treat. 2008 Jul;110(1):127-34
pubmed: 17687648
Breast Cancer Res Treat. 2012 Nov;136(2):331-45
pubmed: 23073759
Histopathology. 2008 Jan;52(1):108-18
pubmed: 18171422
Am J Cancer Res. 2016 Aug 01;6(8):1609-23
pubmed: 27648353
Clin Cancer Res. 2018 May 15;24(10):2276-2284
pubmed: 29506988
Oncotarget. 2014 Jun 15;5(11):3919-30
pubmed: 25003574
Cancer Res. 2008 Jul 15;68(14):5878-87
pubmed: 18632642
Br J Cancer. 1994 Sep;70(3):459-65
pubmed: 8080731
Ann Oncol. 2009 Nov;20(11):1813-7
pubmed: 19553291
Breast Cancer Res Treat. 2009 May;115(1):115-21
pubmed: 18496750
Breast Cancer Res Treat. 2012 Aug;134(3):1149-59
pubmed: 22763464
Chemother Res Pract. 2012;2012:817304
pubmed: 23198146
Ann Surg. 2010 Jun;251(6):1107-16
pubmed: 20485140
Invest New Drugs. 2018 Oct;36(5):848-859
pubmed: 29349598
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Clin Cancer Res. 2021 Jul 15;27(14):3867-3875
pubmed: 33947692
Clin Cancer Res. 2011 Mar 1;17(5):1147-59
pubmed: 21220480
Biochem Biophys Res Commun. 2016 Jan 29;470(1):239-244
pubmed: 26780728
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
Breast Cancer Res. 2009;11(4):R50
pubmed: 19624808
Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75
pubmed: 21342044
Clin Cancer Res. 2021 Jul 1;27(13):3528-3539
pubmed: 33608318
Nat Rev Cancer. 2012 Jul 12;12(8):553-63
pubmed: 22785351
Oncogene. 2009 Mar 12;28(10):1309-19
pubmed: 19151766
Oncogene. 1990 Jul;5(7):953-62
pubmed: 1973830
Breast Cancer Res. 2020 Nov 30;22(1):132
pubmed: 33256808
Stem Cells. 1998;16(6):413-28
pubmed: 9831867
Cancer Res. 2006 Aug 15;66(16):7991-8
pubmed: 16912174
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Methods Mol Biol. 2017;1652:3-35
pubmed: 28791631
J Clin Oncol. 2007 Sep 1;25(25):3816-22
pubmed: 17679728
Oncotarget. 2014 Aug 15;5(15):5934-49
pubmed: 25153719
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Breast Cancer Res. 2008;10(1):R2
pubmed: 18182100
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Biol Proced Online. 2019 Mar 19;21:5
pubmed: 30930695
J Biol Chem. 1975 Jun 10;250(11):4297-304
pubmed: 1126952
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Trends Mol Med. 2002;8(4 Suppl):S19-26
pubmed: 11927283
Br J Cancer. 2014 Jan 21;110(2):384-91
pubmed: 24346286
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
Clin Breast Cancer. 2016 Oct;16(5):349-355
pubmed: 27340049
Oncogene. 1995 May 4;10(9):1813-21
pubmed: 7538656
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Clin Breast Cancer. 2006 Aug;7(3):270-7
pubmed: 16942645
Cancer Cell. 2013 May 13;23(5):603-17
pubmed: 23680147
Cancer Discov. 2022 May 2;12(5):1233-1247
pubmed: 35135829
Mol Cell Biol. 2001 Jul;21(13):4265-75
pubmed: 11390655
Clin Cancer Res. 2014 Mar 15;20(6):1410-6
pubmed: 24520092
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344
pubmed: 33558752
J Clin Oncol. 2013 Jul 10;31(20):2586-92
pubmed: 23733761
Oncotarget. 2019 May 07;10(34):3147-3150
pubmed: 31139328
Anticancer Res. 2003 Sep-Oct;23(5A):3639-50
pubmed: 14666659
Breast Cancer Res Treat. 2005 Jan;89(2):165-72
pubmed: 15692759
Lancet Oncol. 2016 Mar;17(3):357-366
pubmed: 26822398
Eur J Cancer. 2016 Jan;53:144-54
pubmed: 26724641
Clin Breast Cancer. 2016 Feb;16(1):23-30
pubmed: 26381420
Mod Pathol. 2014 Sep;27(9):1212-22
pubmed: 24406864
Clin Cancer Res. 2010 Mar 15;16(6):1904-14
pubmed: 20215537
Eng Life Sci. 2020 Oct 07;21(1-2):37-44
pubmed: 33531889
Ann Oncol. 2020 Jan;31(1):79-87
pubmed: 31912800
Nat Rev Clin Oncol. 2017 Nov;14(11):695-707
pubmed: 28675164
Bioessays. 1998 Jan;20(1):41-8
pubmed: 9504046
Cancer Cell. 2011 Jan 18;19(1):58-71
pubmed: 21215704